Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai To Further Strengthen Strategic Investment In Japan And The U.S.

This article was originally published in PharmAsia News

Executive Summary

At Eisai's third quarter earnings announcement meeting, President Haruo Naito stated that Eisai would further strength strategic investment in the U.S and Japan. Naito does not think that in the following 10 years, BRIC (Brazil, Russia, India and China) countries would have a drug market equal in size to the American market. He also does not believe the four countries would form a drug market cluster similar to the American one. Based on the predication, Eisai is going to set Japanese and American markets as its priorities, and will further invest in these markets to strength their foothold. Last December, Eisai announced its acquisition of U.S. biopharmaceutical company MGI Pharma for $3.9 billion dollars in cash. (Click here for more-Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts